Innovating on Biotech Investment Models: Likely--or Even Possible?
This article was originally published in Start Up
Executive Summary
With the lack of a public market, VCs have grown extremely chary of new investments: are there lessons to be learned for biotech investing from the models employed by device investors or other apparently lower-risk approaches, such as "defined liquidity ventures"?